Shares of Ardelyx (NASDAQ: ARDX) are set to open sharply lower in pre-market trading, plunging 25.94% following the release of the company's disappointing first-quarter 2025 financial results and a subsequent analyst downgrade.
The biopharmaceutical firm's earnings report, released after market close on Thursday, fell significantly short of analyst expectations. Ardelyx reported a quarterly loss of $0.17 per share, missing the consensus estimate of a $0.10 loss by a considerable margin. This represents a 70% negative surprise compared to projections. The company's revenue for the quarter came in at $74.11 million, falling short of analyst estimates of $80.68 million, despite showing a year-over-year increase of 61.1%.
The disappointing results were primarily driven by lower-than-expected product sales. Ardelyx's flagship products, IBSRELA and XPHOZAH, generated sales of $44.40 million and $23.41 million respectively, both falling short of analyst projections. In response to the earnings miss, Raymond James downgraded Ardelyx from Strong Buy to Outperform and cut its price target from $13 to $11, further contributing to the stock's pre-market decline. These factors have raised concerns among investors about Ardelyx's near-term growth prospects and its path to profitability, despite the company's focus on developing innovative treatments for unmet medical needs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.